Gonadorelin's regulatory status depends on the form and how it is used. Some forms or uses are legal, while others are not approved by the U.S. FDA for human use and are not lawful to administer. The specific status of each use is described in the content below.
Status as of July 21, 2026
Gonadorelin is a synthetic decapeptide identical to native gonadotropin-releasing hormone (GnRH), and its documented uses all trace back to a single job: signaling the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The published record groups those uses into three human categories, a diagnostic challenge of pituitary reserve, pulsatile pump therapy for hypothalamic hypogonadism, and an off-label role in testosterone replacement that rests on far thinner evidence than the two approved uses. A defining pharmacologic point runs through all of them: the same molecule stimulates the axis when pulsed and suppresses it when given continuously.
Gonadorelin is a synthetic decapeptide identical to native GnRH whose documented uses fall into diagnostic testing of pituitary gonadotropin reserve, pulsatile pump therapy for hypothalamic hypogonadism, off-label TRT support, and bovine reproductive management, with only the first two carrying US approval.
The approved landscape is narrow and splits across two salt formulations cleared for two different jobs. The hydrochloride salt was a diagnostic agent, given as a single intravenous injection to gauge anterior pituitary reserve, while the acetate salt was a therapeutic agent, delivered by portable pump to induce ovulation in primary hypothalamic amenorrhea. Both branded US products have since been discontinued, so the labeled indications remain the reference point for approved use even though the products themselves are no longer marketed.
| Criteria | Hydrochloride salt | Acetate salt |
|---|---|---|
| Labeled purpose | Diagnostic evaluation of pituitary reserve | Ovulation induction in hypothalamic amenorrhea |
| Delivery | Single intravenous bolus | Pulsatile subcutaneous or intravenous pump |
| Patient population | Suspected hypogonadotropic states | Women with deficient endogenous GnRH |
| US availability | Discontinued | Discontinued |
Gonadorelin's only US-approved indications were diagnostic evaluation of anterior pituitary gonadotropin reserve (hydrochloride salt) and pump-delivered ovulation induction in primary hypothalamic amenorrhea (acetate salt), and both branded products have since been discontinued from the US market.
As a diagnostic tool, gonadorelin drives a controlled, time-limited challenge of the pituitary gonadotroph cells. The GnRH stimulation test reads whether a brisk LH rise follows the dose, which points the problem upstream to the hypothalamus, or whether a blunted response suggests the pituitary itself cannot respond. Its central limitation is that a single test cannot always separate a truly damaged pituitary from one that is only dormant after prolonged lack of endogenous GnRH exposure.
In the standard GnRH stimulation test, a single intravenous gonadorelin bolus is followed by LH and FSH sampling at roughly 15, 30, 45, and 60 minutes, where a brisk LH rise indicates intact pituitary gonadotrophs and a blunted response points to pituitary failure or a chronically GnRH-deprived axis.
Pulsatile gonadorelin is a physiologic replacement strategy for people whose reproductive axis fails specifically at the hypothalamic level, where the pituitary and gonads are competent but the driving GnRH pulse is absent or deficient. The defining requirement is the delivery pattern: native GnRH fires in discrete pulses every 60 to 120 minutes, and the gonadotroph only stays sensitive when stimulated intermittently, so the drug is delivered by a small programmable pump that releases a micro-dose roughly every 90 minutes, day and night. Candidate conditions include idiopathic hypogonadotropic hypogonadism and Kallmann syndrome, in which GnRH-producing neurons fail to develop or migrate properly.
Pulsatile gonadorelin restores gonadotropin secretion only in hypothalamic-level hypogonadism, delivered by a programmable pump releasing a micro-dose roughly every 90 minutes to reproduce the body's natural GnRH rhythm, since continuous exposure would instead desensitize the receptor and suppress secretion.
The off-label interest starts from a specific problem: exogenous testosterone suppresses pituitary LH and FSH through negative feedback, which reduces testicular stimulation and commonly shrinks the testes and impairs sperm production. Clinicians have long added hCG, which mimics LH directly at the testicular Leydig cells, and gonadorelin has been promoted as a substitute that works one step higher by prodding the patient's own pituitary, an appeal that grew when hCG supply and regulatory status were constrained. The pharmacologic catch is that gonadorelin's half-life runs on the order of minutes, so an intermittent injection delivers only a brief pulse rather than hCG's sustained effect.
| Criteria | Gonadorelin | hCG |
|---|---|---|
| Site of action | Pituitary (upstream) | Testicular Leydig cells (direct) |
| Duration per dose | Minutes, a brief pulse | Sustained LH-like effect |
| Evidence base | Mechanistic reasoning, no head-to-head trials | Long-established clinical use |
| Status in TRT | Off-label, evidence-limited | Long-standing off-label practice |
Gonadorelin's off-label use in testosterone replacement therapy rests on mechanistic reasoning and clinical practice patterns rather than head-to-head trials, and its minutes-long half-life means intermittent dosing produces only a brief pulse rather than the sustained LH-like stimulation that hCG delivers.
Everything gonadorelin can and cannot do follows from its being an exact synthetic copy of native GnRH, a ten-amino-acid peptide that binds the gonadotroph receptor and triggers release of stored LH and FSH. Because it is identical to the natural hormone rather than a hardened analog, peptidases clear it within minutes, and that short half-life is what suits it to reproducing natural pulses and a single clean diagnostic challenge while ruling out any sustained hormonal effect. The receptor sets the core rule: intermittent stimulation keeps gonadotrophs responsive, whereas constant or high-dose exposure down-regulates and desensitizes them.
Because gonadorelin is structurally identical to native GnRH with a half-life of minutes, it can only relay a stimulatory signal to a competent pituitary and gonads, making it useless in primary pituitary or gonadal failure and, unlike the long-acting GnRH agonists used to suppress the axis, incapable of producing a sustained hormonal effect.
In veterinary medicine gonadorelin is a routine reproductive tool, most prominently in cattle, where a single intramuscular injection induces an LH surge that ovulates a mature follicle. That action makes it a building block of timed artificial insemination programs and a treatment for ovarian follicular cysts in dairy cows. The underlying pharmacology is the same GnRH-receptor signaling as in humans, but the goal is a reliable scheduled biological effect for breeding efficiency rather than a diagnostic readout.
In cattle, a single intramuscular gonadorelin injection induces an ovulatory LH surge, which makes it a core component of timed artificial insemination protocols such as Ovsynch and a treatment for ovarian follicular cysts in dairy cows.
Gonadorelin is the wrong tool whenever the failure lies below the hypothalamus or whenever the therapeutic goal is suppression rather than stimulation. Because it works only by signaling an intact pituitary, it accomplishes nothing in primary pituitary or gonadal failure, where end-organ hormone replacement is the appropriate path instead. It is equally unsuited to any condition where the aim is to shut the axis down, and practical constraints of pump adherence and product discontinuation narrow its use even further.
Gonadorelin is inappropriate in primary pituitary or gonadal failure and in any condition requiring suppression of the reproductive axis, such as prostate cancer, central precocious puberty, or endometriosis, where a long-acting GnRH agonist or antagonist is indicated instead of its brief pulsatile stimulation.
Educational use only. This article describes what the published scientific and clinical literature reports about Gonadorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
